Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AltheRx Pharmaceuticals Inc.

Safe and highly selective therapy for IBS and OAB

This article was originally published in Start Up

Executive Summary

AltheRx Pharmaceuticals Inc. acquired its lead compound, solabegron, from GlaxoSmithKline in March 2011. Solabegron relaxes smooth muscles by stimulating beta-3 adrenoceptors, a novel mechanism compared with currently available treatments for overactive bladder and irritable bowel syndrome, the first two indications that AltheRx is targeting.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel